Chiesi forms tech partnership with Aliada
The collaboration will focus on multiple enzyme cargoes modified using Aliada’s modular delivery platform
Read More
Tag: Chiesi
Affibody and Chiesi Group partner to develop treatments
Collaboration will focus on innovative therapies for patients with a range of respiratory diseases
Read More
Protalix and Chiesi gain positive opinion for pegunigalsidase alfa
The therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease
Read More
Chiesi’s Trimbow recommended for use within NHS Scotland
The SMC approval brings much-needed boost to asthma sufferers across Scotland
Read More
Chiesi reinforces commitment to reducing emissions
First carbon minimal pMDI is on track with the joint goal of benefitting patients and the planet
Read More
Chiesi launches pilot inhaler recycling scheme in the UK
Scheme will run for 12 months in the Leicester, Leicestershire and Rutland areas
Read More
Chiesi announces two successful sets of asthma data
24% of asthma patients have difficult-to-treat or severe versions of the disease.
Read More
One in three COPD patients believe they would get better care with different disease
One third of patients with chronic obstructive pulmonary disease (COPD) feel they would receive better care if they had cancer, diabetes or heart disease, according to a new Chiesi-sponsored patient survey.
Read More
NICE rejects Chiesi’s Lamzede
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
Read More
EU green light for Chiesi’s Lamzede
European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Read More
Five new medicines backed for EU approval
Five therapies have been backed for approval in the European Union, including two orphan medicines addressing rare conditions.
Read More
COPD survey reveals gaps in care
A survey of 500 people across Britain diagnosed with chronic obstructive pulmonary disease (COPD) has revealed that almost a third (31 percent) feel their treatment is not adequately controlling their condition.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
